Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment

Bolsewig, Katharina; Campo Milán, Marta del

doi:http://dx.doi.org/10.1038/s41467-025-56293-z

Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment

License

Citation

Bolsewig K, Willemse EAJ, Sánchez-Juan P, Rábano A, Martínez M, Doecke JD, Bellomo G, Vermunt L, Alcolea D, Halbgebauer S, In 't Veld S, Mattsson-Carlgren N, Veverova K, Fowler CJ, Boonkamp L, Koel-Simmelink M, Hussainali Z, Ruiters DN, Gaetani L, Toja A, Fortea J, Pijnenburg Y, Lemstra AW, Van Der Flier WM, Hort J, Otto M, Hansson O, Parnetti L, Masters CL, Lleó A, Teunissen CE, Del Campo Milán M. Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment. Nat Commun. 2025;16(1):1139. DOI: 10.1038/s41467-025-56293-z

Abstract

DOPA Decarboxylase (DDC) has been proposed as a cerebrospinal fluid (CSF) biomarker with increased concentrations in Lewy body disorders (LBDs) and highest levels in patients receiving dopaminergic treatment. Here we evaluate plasma DDC, measured by proximity extension assay, and the effect of dopaminergic treatment in three independent LBD (with a focus on dementia with Lewy bodies (DLB) and Parkinson's disease (PD)) cohorts: an autopsy-confirmed cohort (n = 71), a large multicenter, cross-dementia cohort (n = 1498) and a longitudinal cohort with detailed treatment information (n = 66, median follow-up time[IQR] = 4[4, 4] years). Plasma DDC was not altered between different LBDs and other disease groups or controls in absence of treatment. DDC levels increased over time in PD, being significantly associated to higher dosages of dopaminergic treatment. This emphasizes the need to consider treatment effect when analyzing plasma DDC, and suggests that plasma DDC, in contrast to CSF DDC, is of limited use as a diagnostic biomarker for LBD, but could be valuable for treatment monitoring.